## Intended Results / Panel Composition

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships [1]</th>
<th>Detection Frequency [2]</th>
<th>Sample Status [3]</th>
<th>Percentage Correct (All) [4]</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-01</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>97.0</td>
</tr>
<tr>
<td>HPVPRES18C1-02</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_3</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>88.8</td>
</tr>
<tr>
<td>HPVPRES18C1-03</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_2, D1</td>
<td>Detected</td>
<td>CORE</td>
<td>92.5</td>
</tr>
<tr>
<td>HPVPRES18C1-04</td>
<td>HPV Negative</td>
<td>PreservCyt</td>
<td></td>
<td>Negative</td>
<td>CORE</td>
<td>97.8</td>
</tr>
<tr>
<td>HPVPRES18C1-05</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_2, D1</td>
<td>Detected</td>
<td>CORE</td>
<td>93.3</td>
</tr>
<tr>
<td>HPVPRES18C1-06</td>
<td>HPV45</td>
<td>PreservCyt</td>
<td></td>
<td>Detected</td>
<td>CORE</td>
<td>94.8</td>
</tr>
</tbody>
</table>

\[1\] **Sample Relationships**: Indicates the relationships of the samples within this challenge. Dilution series are indicated by ‘DS1’ with each panel member in the dilution series represented by a number in order of titre, where DS1_1 represents the highest titre within that dilution series. Further dilution series are indicated by ‘DS2’ ‘DS3’ etc. If one duplicate pair is present this is indicated by ‘D1’. Further duplicate pairs are indicated by ‘D2’, ‘D3’ etc.

\[2\] **Detection Frequency**: To aid qualitative analysis each panel member is assigned a frequency of detection. This is based on the peer group consensus of all qualitative results returned from participants within the EQA challenge / distribution.

\[3\] **Sample Status**: EQA samples are defined as "CORE" or "EDUCATIONAL". Core proficiency samples are reviewed by the QCMD Scientific Expert(s). This is on the basis of scientific information, clinical relevance, current literature and, where appropriate, professional clinical guidelines. Participating laboratories are expected to report core proficiency samples correctly within the EQA challenge / distribution.

\[4\] **Percentage Correct (All)**: Percentage of datasets (%) reporting the correct qualitative result and the total number of datasets (n) reported for each panel member.

For further details please refer to the current participant manual.

## Your Summary Results

<table>
<thead>
<tr>
<th>EQA Assessment Group [1]</th>
<th>Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core Panel Detection (Qualitative) Score [2]</td>
<td>2</td>
</tr>
</tbody>
</table>

---

[3] Challenge: C1
[4] Analysis Type: Custom
[7] Laboratory: CZ023

QCMD, Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA Tel: +44 (0) 141 945 6474, Fax: +44 (0) 141 945 5795 Web: www.qcmd.org

Page 1 of 13
Issue Date: 02 Aug 2018
Report authorised by the QCMD Executive (1)
A UKAS accredited proficiency testing provider No.4385
### Core Panel Members Results

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Percentage Correct (All)</th>
<th>Your Result</th>
<th>Detection Score</th>
<th>Reported Value</th>
<th>Unitage</th>
<th>Cycle Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV/PRES18C1-01</td>
<td>97.0</td>
<td>Positive</td>
<td>2</td>
<td>Not Applicable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HPV/PRES18C1-03</td>
<td>92.5</td>
<td>Positive</td>
<td>2</td>
<td>Not Applicable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HPV/PRES18C1-04</td>
<td>97.8</td>
<td>Negative</td>
<td>2</td>
<td>Not Applicable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HPV/PRES18C1-05</td>
<td>93.3</td>
<td>Positive</td>
<td>2</td>
<td>Not Applicable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HPV/PRES18C1-06</td>
<td>94.8</td>
<td>Negative</td>
<td>2</td>
<td>Not Applicable</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

[1] EQA Assessment Group: To aid data analysis, participant results are grouped according to the molecular amplification/detection method specified within their molecular workflow for this challenge / distribution. For further details refer to the Additional Information: Individual Panel Member Analysis section of this report.

[2] Core Panel Detection (Qualitative) Score: An overall core panel detection score provided per challenge / distribution.

[3] Quantitative Data (for information only): This is the quantitative value, unitage and cycle threshold you provided when you submitted your results. For qualitative programmes this information is not used as part of your formal EQA assessment.

[4] Percentage Correct (All): Percentage of datasets (%) reporting the correct qualitative results for each panel member.

[5] Your Result: The qualitative result you reported for each sample within this EQA challenge / distribution.

[6] Detection Score: Your detection (qualitative) scores are based on the assigned detection frequency of each panel member, where 0 (zero) is "highly satisfactory" and 3 (three) is "highly unsatisfactory". Scores are provided for individual panel members.

*For further details please refer to the current participant manual.*

### Core Panel Member Score Breakdown

![Detection (Qualitative) Score Breakdown Chart](chart.png)
Core Panel Member Score Breakdown - Detection: This figure gives you a breakdown of the qualitative detection scores for all qualitative datasets returned within this EQA challenge / distribution independent of the EQA assessment group. Panel detection scores are generated from only those panel members that are defined as "CORE".

For further details please refer to the current participant manual.

My Workflow Details

The details of the workflow(s) used to submit your results for this challenge.

<table>
<thead>
<tr>
<th>Name</th>
<th>GeneProof Human Papillomavirus (HPV) PCR Kit - HPVS (v2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>HPVS version</td>
</tr>
<tr>
<td>Targets</td>
<td>V human papillomavirus</td>
</tr>
</tbody>
</table>

**Assays**

- **Extraction** - RBC Bioscience - MagCore HF 16
  - Commercial
    - Kit Manufacturer: RBC
    - Kit Type: 110
- **Amplification** - GeneProof - croBEE Real-Time PCR System
  - Commercial
    - Kit Manufacturer: GeneProof
    - Kit Type: Human Papillomavirus (HPV) PCR Kit
    - Kit Version: HPVS

Educational Panel Members Results

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Qualitative Results</th>
<th>Your Quantitative Data (for information only) [1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-02</td>
<td>88.8</td>
<td>Positive</td>
</tr>
</tbody>
</table>

[1] **Quantitative Data (for information only):** This is the quantitative value, unitage and cycle threshold you provided when you submitted your results. For qualitative programmes this information is not used as part of your formal EQA assessment.

[2] **Percentage Correct (All):** Percentage of datasets (%) reporting the correct qualitative results for each panel member.

[3] **Your Result:** The qualitative result you reported for each sample within this EQA challenge / distribution.

[4] **Detection Score:** Your detection (qualitative) scores are based on the assigned detection frequency of each panel members, where 0 (zero) is "highly satisfactory" and 3 (three) is "highly unsatisfactory". Scores are provided for individual panel members.

For further details please refer to the current participant manual.
Further Programme Details

Number of Participants: 109
Number of Countries: 27
Number of Respondents: 105
Number of Datasets Submitted: 134
Qualitative Results Returned: 134 (100.0%)

EQA Programme Aims
To assess the proficiency of laboratories in the detection of different high risk human papillomavirus (HPV) types within a PreservCyte® matrix.

Feedback and Enquiries
Participants are encouraged to read the QCMD Participants' Manual, which can be downloaded from the QCMD website. Any queries about this report should be addressed to the QCMD Neutral Office (neutraloffice@qcmd.org).
Panel member analysis is separated into CORE samples followed by EDUCATIONAL samples.

**Additional Core Samples Information**

The following section has been categorised as shown below:

Core ► Qualitative

**Individual Panel Member Analysis (Qualitative)**

Qualitative analysis for each panel member is provided in relation to your EQA assessment group. EQA assessment groups are established using the molecular workflow information reported by all participants within this EQA challenge / distribution. The principal level of assessment is at the individual method level which is defined based on your reported "amplification/detection method" and other laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist of 5 or more datasets. If there are not sufficient datasets at the individual method level then your results will be included within a higher EQA assessment group based on whether it is a commercial or in house technology/method. The highest level assessment grouping is "All" participant reported qualitative results.

A breakdown of qualitative results reported by participants on each of the panel members within this EQA challenge / distribution is provided below. You can compare your results to those within your EQA assessment group and those obtained within other EQA assessment groups or to the overall consensus for each sample within this EQA challenge / distribution.
### HPVPRES18C1-01 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-01</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_1</td>
<td>Frequently Detected</td>
<td>CORE</td>
<td>97.0% (134)</td>
</tr>
</tbody>
</table>

**Groups below n=5:**
- AB Analitica (n=4), AB Analitica - AB Analitica AMPLIQUALITY (n=2), AB Analitica - AB Analitica REALQUALITY RQ (n=2), BD Molecular Diagnostics (n=2), BD Molecular Diagnostics - BD Onclarity (n=2), Bio-Rad (n=1), Bio-Rad - Bio-Rad Dx (n=1), Cepheid (n=3), Cepheid - Cepheid Xpert kit (n=3), Clonit (n=1), Clonit - Clonit PCR Reagents (n=1), DiagCor (n=1), DiagCor - DiagCor GeneFlow (n=1), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), Greiner bio one (n=2), Greiner bio one - Greiner bio-one (n=2), Hologic - Hologic Cervista (n=1), Hybridio (n=1), Hybridio - Hybridio GenoArray (n=1), InterLabService (n=1), InterLabService - InterLabService AmpliSens (n=1), KalGen DNA (n=1), KalGen DNA - KalGen DNA PCR Reagents (n=1), NEUMANN (n=1), NEUMANN - NEUMANN Real Time PCR (n=1), QIAGEN (n=4), QIAGEN - QIAGEN Digene HC (n=4), Roche - Roche Linear Array (n=4), Sacace (n=2), Sacace - Sacace Real TM (n=2), Sansure Biotech (n=1), Sansure Biotech - Sansure Real time PCR (n=1), Yaneng BIO (n=1), Yaneng BIO - Yaneng BIO PCR Reagents (n=1), ZJ Bio-Tech (n=1), ZJ Bio-Tech - ZJ Bio-Tech RT PCR (n=1), In-House - Conventional In-House PCR (n=4), In-House - Real-time In-House PCR (n=1)

**Groups Rolled Up:**
- Abbott - Abbott Real Time PCR (n=7), Fujirebio - Fujirebio INNO-LiPA (n=10), Genomica - Genomica CLART (n=5), Seegene - Seegene Real Time PCR (n=23)
HPVPRES18C1-03 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-03</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DG1_2, D1</td>
<td>Detected</td>
<td>CORE</td>
<td>92.5</td>
</tr>
</tbody>
</table>

Groups below n=5: AB Analitica (n=4), AB Analitica - AB Analitica AMPLIQUALITY (n=2), AB Analitica - AB Analitica REALQUALITY RQ (n=2), BD Molecular Diagnostics (n=2), BD Molecular Diagnostics - BD Onclarity (n=2), Bio-Rad (n=1), Bio-Rad - Bio-Rad Dx (n=1), Cepheid (n=3), Cepheid - Cepheid Xpert kit (n=3), Clonit (n=1), Clonit - Clonit PCR Reagents (n=1), DiagCor (n=1), DiagCor - DiagCor GenoFlow (n=1), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), Greiner bio one (n=2), Greiner bio one - Greiner bio-one (n=2), Hologic - Hologic Cervista (n=1), Hybridio (n=1), Hybridio - Hybridio GenoArray (n=1), InterLabService (n=1), InterLabService - InterLabService AmplicSens (n=1), KalGen DNA (n=1), KalGen DNA - KalGen DNA PCR Reagents (n=1), NEUMANN (n=1), NEUMANN - NEUMANN Real Time PCR (n=1), QIAGEN (n=4), QIAGEN - QIAGEN Digene HC (n=4), Roche - Roche Linear Array (n=4), Sacace (n=2), Sacace - Sacace Real TM (n=2), Sansure Biotech (n=1), Sansure Biotech - Sansure Real time PCR (n=1), Yaneng BIO (n=1), Yaneng BIO - Yaneng BIO PCR Reagents (n=1), ZJ Bio-Tech (n=1), ZJ Bio-Tech - ZJ Bio-Tech RT PCR (n=1), In-House - Conventional In-House PCR (n=4), In-House - Real-time In-House PCR (n=1)

Groups Rolled Up: Abbott - Abbott Real Time PCR (n=7), Fujirebio - Fujirebio INNO-LiPA (n=10), Genomica - Genomica CLART (n=5), Seegene - Seegene Real Time PCR (n=23)
### HPVPRES18C1-04 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-04</td>
<td>HPV Negative</td>
<td>PreservCyt</td>
<td>Negative</td>
<td>CORE</td>
<td>97.8</td>
<td>134</td>
</tr>
</tbody>
</table>

#### Groups below n=5:
- AB Analitica (n=4)
- AB Analitica - AB Analitica AMPLIQUALITY (n=2)
- AB Analitica - AB Analitica REALQUALITY RQ (n=2)
- BD Molecular Diagnostics (n=2)
- BD Molecular Diagnostics - BD Onclarity (n=2)
- Bio-Rad (n=1)
- Bio-Rad - Bio-Rad Dx (n=1)
- Cepheid (n=3)
- Cepheid - Cepheid Xpert kit (n=3)
- Clonit (n=1)
- Clonit - Clonit PCR Reagents (n=1)
- DiagCor (n=1)
- DiagCor - DiagCor GenoFlow (n=1)
- GeneProof (n=1)
- GeneProof - GeneProof Real Time PCR kit (n=1)
- Greiner bio one (n=2)
- Greiner bio one - Greiner bio-one (n=2)
- Hologic (n=3)
- Hologic APTIMA (n=1)
- Roche (n=2)
- Roche Cobas 4800 (n=1)
- Seegene (n=1)
- In-House (n=4)
- In-House - Real-time In-House PCR (n=1)

#### Groups Rolled Up:
- Abbott - Abbott Real Time PCR (n=7)
- Fujirebio - Fujirebio INNO-LiPA (n=10)
- Genomica - Genomica CLART (n=5)
- Seegene - Seegene Real Time PCR (n=23)
### HPVPRES18C1-05 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-05</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DG1_2, D1</td>
<td>Detected</td>
<td>CORE</td>
<td>93.3 / 134</td>
</tr>
</tbody>
</table>

#### Groups below n=5:
- AB Analitica (n=4), AB Analitica - AB Analitica AMPLIQUALITY (n=2), AB Analitica - AB Analitica REALQUALITY RQ (n=2), BD Molecular Diagnostics (n=2), BD Molecular Diagnostics - BD Onclarity (n=2), Bio-Rad (n=1), Bio-Rad - Bio-Rad Dx (n=1), Cepheid (n=3), Cepheid - Cepheid Xpert kit (n=3), Clonit (n=1), Clonit - Clonit PCR Reagents (n=1), DiagCor (n=1), DiagCor - DiagCor GenoFlow (n=1), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), Greiner bio one (n=2), Greiner bio one - Greiner bio-one (n=2), Hologic - Hologic Cervista (n=1), Hybridio (n=1), Hybridio - Hybridio GenoArray (n=1), InterLabService (n=1), InterLabService - InterLabService AmpliSens (n=1), KalGen DNA (n=1), KalGen DNA - KalGen DNA PCR Reagents (n=1), NEUMANN (n=1), NEUMANN - NEUMANN Real Time PCR (n=1), QIAGEN (n=4), QIAGEN - QIAGEN Digene HC (n=4), Roche - Roche Linear Array (n=4), Sacace (n=2), Sacace - Sacace Real TM (n=2), Sansure Biotech (n=1), Sansure Biotech - Sansure Real time PCR (n=1), Yaneng BIO (n=1), Yaneng BIO - Yaneng BIO PCR Reagents (n=1), ZJ Bio-Tech (n=1), ZJ Bio-Tech - ZJ Bio-Tech RT PCR (n=1), In-House - Conventional In-House PCR (n=4), In-House - Real-time In-House PCR (n=1)

#### Groups Rolled Up:
- Abbott - Abbott Real Time PCR (n=7), Fujirebio - Fujirebio INNO-LiPA (n=10), Genomica - Genomica CLART (n=5), Seegene - Seegene Real Time PCR (n=23)
HPVPRES18C1-06 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-06</td>
<td>HPV45</td>
<td>PreservCyt</td>
<td>Detected</td>
<td>CORE</td>
<td>94.8</td>
<td>134</td>
</tr>
</tbody>
</table>

Groups below n=5: AB Analitica (n=4), AB Analitica - AB Analitica AMPLIQUALITY (n=2), AB Analitica - AB Analitica REALQUALITY RQ (n=2), BD Molecular Diagnostics (n=2), BD Molecular Diagnostics - BD Onclarity (n=2), Bio-Rad (n=1), Bio-Rad - Bio-Rad Dx (n=1), Cepheid (n=3), Cepheid - Cepheid Xpert kit (n=3), Clonit (n=1), Clonit - Clonit PCR Reagents (n=1), DiagCor (n=1), DiagCor - DiagCor GenoFlow (n=1), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), Greiner bio one (n=2), Greiner bio one - Greiner bio-one (n=2), Hologic - Hologic Cervista (n=1), Hybridio (n=1), Hybridio - Hybridio GenoArray (n=1), InterLabService (n=1), InterLabService - InterLabService AmpliSens (n=1), KalGen DNA (n=1), KalGen DNA - KalGen DNA PCR Reagents (n=1), NEUMANN (n=1), NEUMANN - NEUMANN Real Time PCR (n=1), QIAGEN (n=4), QIAGEN - QIAGEN Digene HC (n=4), Roche - Roche Linear Array (n=4), Sacace (n=2), Sacace - Sacace Real TM (n=2), Sansure Biotech (n=1), Sansure Biotech - Sansure Real time PCR (n=1), Yaneng BIO (n=1), Yaneng BIO - Yaneng BIO PCR Reagents (n=1), ZJ Bio-Tech (n=1), ZJ Bio-Tech - ZJ Bio-Tech RT PCR (n=1), In-House - Conventional In-House PCR (n=4), In-House - Real-time In-House PCR (n=1)

Groups Rolled Up: Abbott - Abbott Real Time PCR (n=7), Fujirebio - Fujirebio INNO-LiPA (n=10), Genomica - Genomica CLART (n=5), Seegene - Seegene Real Time PCR (n=23)
Additional Educational Samples Information

The following section has been categorised as shown below:

Educational ► Qualitative

Individual Panel Member Analysis (Qualitative)

Qualitative analysis for each panel member is provided in relation to your EQA assessment group. EQA assessment groups are established using the molecular workflow information reported by all participants within this EQA challenge / distribution. The principal level of assessment is at the individual method level which is defined based on your reported “amplification/detection method” and other laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist of 5 or more datasets. If there are not sufficient datasets at the individual method level then your results will be included within a higher EQA assessment group based on whether it is a commercial or in house technology/method. The highest level assessment grouping is “All” participant reported qualitative results.

A breakdown of qualitative results reported by participants on each of the panel members within this EQA challenge / distribution is provided below. You can compare your results to those within your EQA assessment group and those obtained within other EQA assessment groups or to the overall consensus for each sample within this EQA challenge / distribution.
# HPVPRES18C1-02 - Qualitative Results Breakdown

<table>
<thead>
<tr>
<th>Sample Code</th>
<th>Sample Content</th>
<th>Matrix</th>
<th>Sample Relationships</th>
<th>Detection Frequency</th>
<th>Sample Status</th>
<th>Percentage Correct (All)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPVPRES18C1-02</td>
<td>HPV18 (Hela)</td>
<td>PreservCyt</td>
<td>DS1_3</td>
<td>Detected</td>
<td>EDUCATIONAL</td>
<td>88.8%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Groups below n=5:</th>
<th>Groups Rolled Up:</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB Analitica (n=4), AB Analitica - AB Analitica AMPLIQUALITY (n=2), AB Analitica - AB Analitica REALQUALITY RQ (n=2), BD Molecular Diagnostics (n=2), BD Molecular Diagnostics - BD Oclarity (n=2), Bio-Rad (n=1), Bio-Rad - Bio-Rad Dx (n=1), Cepheid (n=3), Cepheid - Cepheid Xpert kit (n=3), Clonit (n=1), Clonit - Clonit PCR Reagents (n=1), DiagCor (n=1), DiagCor - DiagCor GenoFlow (n=1), GeneProof (n=1), GeneProof - GeneProof Real Time PCR kit (n=1), Greiner bio one (n=2), Greiner bio one - Greiner bio-one (n=2), Hologic - Hologic Cervista (n=1), Hybridio (n=1), Hybridio - Hybridio GenoArray (n=1), InterLabService (n=1), InterLabService - InterLabService AmpliSens (n=1), KalGen DNA (n=1), KalGen DNA - KalGen DNA PCR Reagents (n=1), NEUMANN (n=1), NEUMANN - NEUMANN Real Time PCR (n=1), QIAGEN (n=4), QIAGEN - QIAGEN Digene HC (n=4), Roche - Roche Linear Array (n=4), Sacace (n=2), Sacace - Sacace Real TM (n=2), Sansure Biotech (n=1), Sansure Biotech - Sansure Real time PCR (n=1), Yaneng BIO (n=1), Yaneng BIO - Yaneng BIO PCR Reagents (n=1), ZJ Bio-Tech (n=1), ZJ Bio-Tech - ZJ Bio-Tech RT PCR (n=1), In-House - Conventional In-House PCR (n=4), In-House - Real-time In-House PCR (n=1)</td>
<td></td>
</tr>
<tr>
<td>Abbott</td>
<td>Abbott - Abbott Real Time PCR (n=7), Fujirebio - Fujirebio INNO-LiPA (n=10), Genomica - Genomica CLART (n=5), Seegene - Seegene Real Time PCR (n=23)</td>
</tr>
</tbody>
</table>

![Bar chart showing percentage of incorrect and correct results for various groups.](image-url)
QCMD © 2018. The QCMD EQA programme samples, associated reports and data generated during this programme are intended for External Quality Assessment (EQA) and Proficiency Testing (PT) purposes only. QCMD operates according to a strict Code of Practice which is in line with ISO/IEC 17043 and associated standards. Data reported in QCMD programmes is representative of a laboratory's standard diagnostic testing protocols irrespective of the technology they use. The data provided in the reports are based on technical information provided by the individual laboratories as part of the assessment process, as such it does not constitute a formal technology method comparison. All text and images produced by QCMD are the property of QCMD unless otherwise stated.

The reproduction and use of these materials is not permitted without the express written consent of QCMD. The use of the information provided in QCMD reports for commercial purposes is strictly prohibited.